Teleflex hit with FDA warning letter over respiratory devices

The FDA has handed a warning letter to Teleflex ($TFX), citing manufacturing issues at an Illinois plant that produces nebulizers, humidifiers and other respiratory technologies. In its letter, the agency details a host of problems with the company's corrective actions, process verification and self-inspections. Following an earlier FDA visit, Teleflex submitted a list of fixes, but the agency found them inadequate, and now the firm has 15 days to address the violations. Letter

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.